275 related articles for article (PubMed ID: 31722862)
1. High rates of antiretroviral coverage and virological suppression in HIV-1-infected children and adolescents.
Soumah A; Avettand-Fenoel V; Veber F; Moshous D; Mahlaoui N; Blanche S; Frange P
Med Mal Infect; 2020 May; 50(3):269-273. PubMed ID: 31722862
[TBL] [Abstract][Full Text] [Related]
2. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
[TBL] [Abstract][Full Text] [Related]
3. Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.
Schoffelen AF; Wensing AM; Tempelman HA; Geelen SP; Hoepelman AI; Barth RE
PLoS One; 2013; 8(3):e58526. PubMed ID: 23505529
[TBL] [Abstract][Full Text] [Related]
4. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.
El-Khatib Z; Ekstrom AM; Ledwaba J; Mohapi L; Laher F; Karstaedt A; Charalambous S; Petzold M; Katzenstein D; Morris L
AIDS; 2010 Jul; 24(11):1679-87. PubMed ID: 20453629
[TBL] [Abstract][Full Text] [Related]
5. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
7. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children.
Mulu A; Liebert UG; Maier M
BMC Infect Dis; 2014 Jan; 14():28. PubMed ID: 24422906
[TBL] [Abstract][Full Text] [Related]
8. Respective roles of migration and social deprivation for virological non-suppression in HIV-infected adults on antiretroviral therapy in France.
Raho-Moussa M; Guiguet M; Michaud C; Honoré P; Palacios C; Boué F; Azghay M; Kansau I; Chambrin V; Kandel T; Favier M; Miekoutima E; Sayre N; Pignon C; Shoai M; Bouchaud O; Abgrall S
PLoS One; 2019; 14(3):e0213019. PubMed ID: 30845270
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.
Briand C; Dollfus C; Faye A; Kantor E; Avettand-Fenoel V; Caseris M; Descamps D; Schneider V; Tabone MD; Vaudre G; Veber F; Blanche S; Frange P
J Antimicrob Chemother; 2017 Mar; 72(3):837-843. PubMed ID: 27999017
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
[TBL] [Abstract][Full Text] [Related]
11. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
[TBL] [Abstract][Full Text] [Related]
12. Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic.
Charpentier C; Gody JC; Mbitikon O; Moussa S; Matta M; Péré H; Fournier J; Longo Jde D; Bélec L
AIDS Res Hum Retroviruses; 2012 Jan; 28(1):87-94. PubMed ID: 21599597
[TBL] [Abstract][Full Text] [Related]
13. Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa.
Fofana DB; d'Almeida M; Lambert-Niclot S; Peytavin G; Girard PM; Lafia B; Zohoun-Guidigbi L; Keke RK; Soulie C; Marcelin AG; Morand-Joubert L
J Antimicrob Chemother; 2018 Nov; 73(11):3143-3147. PubMed ID: 30060186
[TBL] [Abstract][Full Text] [Related]
14. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.
Hermans LE; Carmona S; Nijhuis M; Tempelman HA; Richman DD; Moorhouse M; Grobbee DE; Venter WDF; Wensing AMJ
PLoS Med; 2020 Feb; 17(2):e1003037. PubMed ID: 32097428
[TBL] [Abstract][Full Text] [Related]
15. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
[TBL] [Abstract][Full Text] [Related]
16. Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat".
Fokam J; Sosso SM; Yagai B; Billong SC; Djubgang Mbadie RE; Kamgaing Simo R; Edimo SV; Nka AD; Tiga Ayissi A; Yimga JF; Takou D; Moudourou S; Ngo Nemb M; Nfetam Elat JB; Santoro MM; Perno CF; Colizzi V; Ndjolo A
AIDS Res Ther; 2019 Nov; 16(1):36. PubMed ID: 31744517
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 low-level viremia affects T cell activation rather than T cell development in school-age children, adolescents, and young adults during antiretroviral therapy.
Han J; Mu W; Zhao H; Hao Y; Song C; Zhou H; Sun X; Li G; Dai G; Zhang Y; Zhang F; Zeng H
Int J Infect Dis; 2020 Feb; 91():210-217. PubMed ID: 31821891
[TBL] [Abstract][Full Text] [Related]
18. Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort study.
Lyatuu GW; Mwashemele SZ; Urrio R; Naburi H; Kashmir N; Machumi L; Kibao A; Sellah Z; Ulenga N; Orsini N; Biberfeld G; Kilewo C; Ekström AM
Lancet HIV; 2021 May; 8(5):e256-e265. PubMed ID: 33581776
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.
Ngo-Giang-Huong N; Wittkop L; Judd A; Reiss P; Goetghebuer T; Duiculescu D; Noguera-Julian A; Marczynska M; Giacquinto C; Ene L; Ramos JT; Cellerai C; Klimkait T; Brichard B; Valerius N; Sabin C; Teira R; Obel N; Stephan C; de Wit S; Thorne C; Gibb D; Schwimmer C; Campbell MA; Pillay D; Lallemant M;
BMC Infect Dis; 2016 Nov; 16(1):654. PubMed ID: 27825316
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
